Johnson & Johnson posts Q3 2026 results, lifts full‑year sales and earnings outlook
+2 new sources since this summary was written
Johnson & Johnson reported third‑quarter 2026 revenue of $25.4 billion, a 5.9% year‑over‑year increase, while net profit fell to $210 million after a one‑time charge linked to talc litigation and the Firefly Bio acquisition. Adjusted earnings per share were $2.59, beating consensus. The company raised its 2026 guidance to $101.0‑$101.4 billion of sales and $11.05‑$11.15 of adjusted EPS.
Why it matters
The higher guidance expands the earnings outlook for the year, meaning analysts will model larger cash flows and investors may adjust valuation models accordingly. The special charge, however, signals ongoing litigation risk that could affect future profitability.
Key facts
- 1Q3 2026 reported sales were $25.4 billion, up 5.9% from the prior year. marketscreener.com
- 2Net earnings for the quarter were $210 million, a 95.9% decline year over year. marketscreener.com
- 3Adjusted EPS (non‑GAAP) was $2.59, beating estimates by $0.06. investing.com
- 4The company cited a one‑time charge related to talc litigation and the Firefly Bio acquisition as drivers of the earnings drop. sec.gov
- 5Full‑year 2026 sales guidance was raised to a range of $101.0 billion‑$101.4 billion. marketscreener.com
- 6Adjusted EPS guidance for 2026 was increased to $11.05‑$11.15 per share. marketscreener.com
Summary written by AlphAI AI Desk from 18 of 18 sources. Not investment advice. Figures are as stated by the linked sources.